Medix Biochemica: 40 Years of Innovation, Sustainability, and Global Impact in IVD

08 April 2025

Celebrating 40 Years!

We are proud to enter our 40th year in the IVD industry. As we mark this milestone, we reflect on our journey, achievements, and future.
Over the coming months, we’ll share insights and fun tidbits from our teams worldwide—after all, it’s our people who define us. Stay connected by subscribing to our newsletter!

Read on to learn about the values that have shaped our past and will guide us in the years ahead.

Medix Biochemica: From Visionary Beginnings to Global Leadership

Founded in Finland in 1985, Medix Biochemica set out to revolutionize the in vitro diagnostics (IVD) industry, inspired by the groundbreaking hybridoma technique developed by Nobel laureates Köhler and Milstein.¹ As the first to industrialize high-quality monoclonal antibody production, the company has grown into a global leader, driving innovation, quality, customer collaboration, and supplying raw materials to nearly 80 countries - enabling 1 million daily diagnostic tests worldwide.²

Read more about Medix Biochemica's history.

Strategic Growth To Best Serve Our Customers

Always with the vision of becoming the first-choice raw material partner to the IVD industry at the forefront, over the last several years, Medix Biochemica has strategically expanded its portfolio to include antigens, clinical enzymes, biospecimens, molecular diagnostic reagents, and base matrices; drastically expanded the offerings within targeted high-impact clinical areas like inflammation, infectious diseases, and drugs of abuse while strengthening local presence in the US, Europe, and China, enhancing offerings and service for customers worldwide.³ If there is an IVD thing you need, chances are We IVDo That.

Innovation Driving Industry Advancements

Innovation and collaboration drive Medix Biochemica's advancements in the IVD industry. Through cutting-edge R&D, the company delivers state-of-the-art solutions, positioning itself as a vital partner in antibody and enzyme development for diagnostic tools. Highlights include rescuing monoclonal antibodies via DNA sequence recovery and creating recombinant antibodies for immunoPET applications, underscoring its role in advancing technology and improving global patient care.⁴

Unlock the potential of our cutting-edge innovations to transform your work. Contact us today to learn more about how we can collaborate and help you achieve your goals!

A Sustainable Future

As Medix Biochemica marks 40 years, sustainability is central to its growth strategy. The company prioritizes eco-friendly practices by optimizing manufacturing, reducing waste, and minimizing its carbon footprint. Through ongoing R&D investments in sustainable technologies, Medix Biochemica aims to lead the IVD industry in advancing diagnostics while protecting the environment.⁵

Read more about Medix Biochemica's sustainability approach, and how our actions have earned us a Silver Medal in EcoVadis Sustainability Rating.⁵

Global Impact and Vision

With a presence in nearly 80 countries and eight international sites, Medix Biochemica’s portfolio addresses diverse healthcare needs, supporting global diagnostics like COVID-19 testing. The company remains committed to driving innovation, expanding its reach, and fostering collaborations to make diagnostics more accessible and accurate.³

Join Us in Shaping the Future

Looking ahead, Medix Biochemica remains focused on innovation and expanding its global healthcare impact. Through strategic growth, advances in technology, and partnerships with industry leaders, the company aims to create more accurate, accessible, and sustainable diagnostic tools. Celebrating 40 years of progress, Medix Biochemica remains committed to being the first-choice raw material partner for the IVD industry.

Stay updated on our journey of innovation and global impact by subscribing to our articles.